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Juvenile bipolar disorder (BD) is reported to be more
treatment-resistant than adult BD, and to show poorer
outcome. Predictors of treatment non-response in early
onset BD are not well defined. Many potential domains of
variables may be considered. Age, gender and age at onset
of BD can affect both clinical presentation and pattern of
comorbidity, and both these issues may affect the phar-
macological response. Some features, which in adult
patients with BD are considered predictors of poor treat-
ment response, such as severity, mixed states, psychotic
symptoms, and co-morbid substance abuse are particu-
larly frequent in youths, and they also may influence
pharmacological response in children and adolescents as
well. We explored this issue in a study, conducted in the
last 3 years, aimed to explore the role of lifetime comorbid
externalizing and internalizing disorders as possible pre-
dictors of treatment non-response, in bipolar children
and adolescents with manic or mixed episodes. Non-
responders had more frequently co-morbid conduct dis-
order and/or ADHD. Furthermore, they were globally
more severe at baseline and required more frequent addi-
tion of antipsychotic medications than treatment-
responder patients. Co-morbid anxiety disorders in our
sample did not predict treatment resistance. Interestingly,
anxiety disorders and CD were inversely related, with the
number of anxiety disorders significantly lower in subjects
without CD comorbidity. The use of antipsychotics was
associated with treatment non-response, and it was prob-
ably related to the severity of the subjects who received
these drugs (i.e. higher prevalence of impulsivity, psycho-
motor agitation, behavioral problems, psychotic symp-
toms). Different mechanisms can be involved in
treatment-resistance of bipolar subjects with co-morbid
externalizing disorders. BD plus externalizing disorders
may represent a specific subtype, with earlier-onset and
resistance to traditional anti-manic and mood stabilizing
drugs. Poorer treatment response in BD with co-occurring
externalizing disorders may be also accounted for by a
more problematic compliance to treatment. Several co-
morbidities with negative prognostic implications (i.e.
substance abuse, antisocial behaviors), which are more
frequent in bipolar patients with externalizing disorders,
may further affect clinical course. Follow-up studies with
larger samples of subjects with BD and/or externalizing
disorders appropriately treated with different options are
needed to address this important issue. Additional stimu-
lant medication after adequate coverage with mood stabi-
lizers might represent one rational approach to this group
of refractory bipolar children.
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